[HTML][HTML] Kinetics of protective antibodies are determined by the viral surface antigen

DD Pinschewer, M Perez, E Jeetendra… - The Journal of …, 2004 - Am Soc Clin Investig
DD Pinschewer, M Perez, E Jeetendra, T Bächi, E Horvath, H Hengartner, MA Whitt
The Journal of clinical investigation, 2004Am Soc Clin Investig
Delayed and weak virus neutralizing antibody (nAb) responses represent a hallmark
correlating not only with the establishment of persistent infection but also with unsuccessful
vaccine development. Using a reverse genetic approach, we evaluated possible underlying
mechanisms in 2 widely studied viral infection models. Swapping the glycoproteins (GPs) of
lymphocytic choriomeningitis virus (LCMV, naturally persisting, noncytolytic, inefficient nAb
inducer) and vesicular stomatitis virus (VSV, nonpersisting, cytolytic, potent nAb inducer) …
Delayed and weak virus neutralizing antibody (nAb) responses represent a hallmark correlating not only with the establishment of persistent infection but also with unsuccessful vaccine development. Using a reverse genetic approach, we evaluated possible underlying mechanisms in 2 widely studied viral infection models. Swapping the glycoproteins (GPs) of lymphocytic choriomeningitis virus (LCMV, naturally persisting, noncytolytic, inefficient nAb inducer) and vesicular stomatitis virus (VSV, nonpersisting, cytolytic, potent nAb inducer) transferred the only target of nAb’s from either virus to the other. We analyzed the nAb response to each of the 2 recombinant and parent viruses in infected mice and found that nAb kinetics were solely determined by the viral surface GP and not by the virus backbone. Moreover, the slowly and poorly nAb-triggering LCMV virion was a potent immunogenic matrix for the more antigenic VSV-GP. These findings indicate that the viral GP determines nAb kinetics largely independently of the specific viral infection context. They further suggest that structural features of viral GPs or coevolutionary adaptation of the virus’s GP to the host’s naive B cell repertoire, or both, may critically limit nAb kinetics and improvement of vaccine efficacy.
The Journal of Clinical Investigation